The pCR increase translated into an improved disease-free survival (DFS) especially for patients with triple-negative breast cancer (TNBC) but also hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer.9 Here, ERBB2 is linked to triple-negative breast carcinoma.